Literature DB >> 26812570

Expanded Access Through Cancer Trials Support Unit to Children's Oncology Group Sarcoma Trial AEWS1031 for Adolescents and Young Adults.

Leo Mascarenhas1, Mason C Bond2, Nita L Seibel3.   

Abstract

Entities:  

Year:  2011        PMID： 26812570      PMCID： PMC4976716          DOI： 10.1089/jayao.2011.1502

Source DB:  PubMed          Journal:  J Adolesc Young Adult Oncol        ISSN： 2156-5333            Impact factor:   2.223


× No keyword cloud information.
  8 in total

1.  Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study.

Authors:  M E Nesbit; E A Gehan; E O Burgert; T J Vietti; A Cangir; M Tefft; R Evans; P Thomas; F B Askin; J M Kissane
Journal:  J Clin Oncol       Date:  1990-10       Impact factor: 44.544

2.  Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

Authors:  Andrea Hunold; Nicole Weddeling; Michael Paulussen; Andreas Ranft; Caren Liebscher; Herbert Jürgens
Journal:  Pediatr Blood Cancer       Date:  2006-11       Impact factor: 3.167

3.  Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II.

Authors:  E O Burgert; M E Nesbit; L A Garnsey; E A Gehan; J Herrmann; T J Vietti; A Cangir; M Tefft; R Evans; P Thomas
Journal:  J Clin Oncol       Date:  1990-09       Impact factor: 44.544

4.  Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.

Authors:  R L Saylors; K C Stine; J Sullivan; J L Kepner; D A Wall; M L Bernstein; M B Harris; R Hayashi; T J Vietti
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

5.  Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.

Authors:  Mark L Bernstein; Meenakshi Devidas; Dominique Lafreniere; Abdul-Kader Souid; Paul A Meyers; Mark Gebhardt; Kimo Stine; Richard Nicholas; Elizabeth J Perlman; Ronald Dubowy; Irving W Wainer; Paul S Dickman; Michael P Link; Allen Goorin; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2006-01-01       Impact factor: 44.544

6.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

Authors:  Holcombe E Grier; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; James S Miser
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

7.  Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.

Authors:  Linda Granowetter; Richard Womer; Meenakshi Devidas; Mark Krailo; Chenguang Wang; Mark Bernstein; Neyssa Marina; Patrick Leavey; Mark Gebhardt; John Healey; Robert Cooper Shamberger; Allen Goorin; James Miser; James Meyer; Carola A S Arndt; Scott Sailer; Karen Marcus; Elizabeth Perlman; Paul Dickman; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

8.  EWS rearrangement in Ewing's sarcoma and peripheral neuroectodermal tumor. Molecular detection and correlation with cytogenetic analysis and MIC2 expression.

Authors:  M Ladanyi; R Lewis; P Garin-Chesa; W J Rettig; A G Huvos; J H Healey; S C Jhanwar
Journal:  Diagn Mol Pathol       Date:  1993-09
  8 in total
  2 in total

Review 1.  Adolescent and Young Adult Oral Maxillofacial Tumors: A Single-Institution Case Series and Literature Review.

Authors:  Anil P George; Michael R Markiewicz; Steven Garzon; Daniel K Choi
Journal:  J Adolesc Young Adult Oncol       Date:  2019-12-20       Impact factor: 2.223

Review 2.  Desmoplastic Small Round Cell Tumor Presenting as an Ocular Mass: Unusual Localization and Remarkable Surgical Approach.

Authors:  H Bengu Cobanoglu; Ehab Y Hanna; Diana Bell; Bita Esmaeli
Journal:  Curr Oncol Rep       Date:  2017-10-18       Impact factor: 5.075
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.